[{"path":"/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceutical-limited-issues-voluntary-nationwide-consumer-level-recall-losartan-potassium","field_change_date_2":"06/26/2019","field_brand_name":"<a href=\"/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceutical-limited-issues-voluntary-nationwide-consumer-level-recall-losartan-potassium\">Macleods</a>","field_product_description":"Losartan Potassium USP tablets and Losartan Potassium/Hydrochlorothiazide combination tablets","field_recall_reason_description":"Presence of NMBA impurity","field_recall_reason":"Unapproved Ingredient","field_company_name":"Macleods Pharmaceutical  Limited","field_product_type":"Generic Drugs","term_node_tid":"Generic Drugs","field_regulated_product_field":"Drugs","all-terms-rewrite":"Drugs, Generic Drugs","publicationDate":"2019-06-26T04:00:00.000Z","link":"https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceutical-limited-issues-voluntary-nationwide-consumer-level-recall-losartan-potassium","canonicalId":"e38c42a512823d32ed67b706cfb883a6726fe860085ab82b5f55ca6ed23af646","title":"Macleods Pharmaceutical Limited Issues\tVoluntary Nationwide Consumer Level Recall of Losartan Potassium 50mg and Losartan Potassium/Hydrochlorothiazide\tcombination Tablets 50mg/12.5mg, 100mg/12.5mg and 100mg/25mg due to detection of NMBA (N-Nitroso-NÂ­ Methyl-4-aminobutyric acid) Impurity.","description":"Macleods Pharmaceuticals Limited has initiated a voluntary recall in the United States, to the patient level, of 32 lots of Losartan Potassium USP Tablets (2 lots of 50mg strength) and Losartan Potassium/Hydrochlorothiazide combination Tablets","feedName":"fda","feedSource":"fda","categories":[]}]